Suppr超能文献

A SPECIAL MEETING REVIEW EDITION: Highlights in Crohn's Disease and Ulcerative Colitis: Digestive Disease Week 2012 May 19-22, 2012 • San Diego, CaliforniaSpecial Reporting on:• Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active UC: PURSUIT-SC• The Future of IBD Therapy: Individualized and Optimized Therapy and Novel Mechanisms• Infliximab Concentration and Clinical Outcome in Patients with UC• Vedolizumab Induction Therapy for UC: Results of GEMINI I, A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase III Trial• Novel Infliximab and Antibody-to-lnfliximab Assays Are Predictive of Disease Activity in Patients with CD• Accelerated Step-Care Therapy with Early Azathioprine Versus Conventional Step-Care Therapy in CD• PIANO: A 1,000-Patient Prospective Registry of Pregnancy Outcomes in Women with IBD Exposed to Immunomodulators and Biologic TherapyPLUS Meeting Abstract Summaries With Expert Commentary by: William J. Sandborn, MDChief of the Division of Gastroenterology Director of the UCSD IBD Center UC San Diego Health System La Jolla, California.

出版信息

Gastroenterol Hepatol (N Y). 2012 Aug;8(8 Suppl 5):1-24.

PMID:24847182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4024246/
Abstract
摘要

相似文献

1
A SPECIAL MEETING REVIEW EDITION: Highlights in Crohn's Disease and Ulcerative Colitis: Digestive Disease Week 2012 May 19-22, 2012 • San Diego, CaliforniaSpecial Reporting on:• Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active UC: PURSUIT-SC• The Future of IBD Therapy: Individualized and Optimized Therapy and Novel Mechanisms• Infliximab Concentration and Clinical Outcome in Patients with UC• Vedolizumab Induction Therapy for UC: Results of GEMINI I, A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase III Trial• Novel Infliximab and Antibody-to-lnfliximab Assays Are Predictive of Disease Activity in Patients with CD• Accelerated Step-Care Therapy with Early Azathioprine Versus Conventional Step-Care Therapy in CD• PIANO: A 1,000-Patient Prospective Registry of Pregnancy Outcomes in Women with IBD Exposed to Immunomodulators and Biologic TherapyPLUS Meeting Abstract Summaries With Expert Commentary by: William J. Sandborn, MDChief of the Division of Gastroenterology Director of the UCSD IBD Center UC San Diego Health System La Jolla, California.
Gastroenterol Hepatol (N Y). 2012 Aug;8(8 Suppl 5):1-24.
2
A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2012May 19-22, 2012 • San Diego, CaliforniaSpecial Reporting on:• Novel Infliximab and Antibody-to-lnfliximab Assays Are Predictive of Disease Activity in Patients with Crohn's Disease• Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated with Infliximab Maintenance Therapy• Putting It Together: Drug Levels and Disease Activity to Tailor Therapy• Infliximab Concentration and Clinical Outcome in Patients with Ulcerative ColitisPLUS Meeting Abstract Summaries With Expert Commentary by: William J. Sandborn, MDChief of the Division of GastroenterologyDirector of the UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.
Gastroenterol Hepatol (N Y). 2012 Jul;8(7 Suppl 4):1-12.
3
A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting: Digestive Disease Week 2014 May 3-6, 2014 • Chicago, Illinois: Special Reporting on:• Therapeutic Monitoring of Anti-TNF Levels and Antibodies to Predict Response and Achieve Mucosal Healing• Prospective Therapeutic Drug Monitoring and Optimization of Infliximab Maintenance Therapy in IBD• Classification of Non-IBD, Crohn's Disease and Ulcerative Colitis in a Young Patient Population Using a Multi-Marker Diagnostic Panel• Persistence of Antibodies to Infliximab for More Than Two Months Predicts Loss of Response to Infliximab in Inflammatory Bowel Diseases• Pre-Operative Serological Markers May Predict Postoperative Crohn's Disease Recurrence: Results From a Prospective Mono-Centric Trial• Antibodies and Levels of Biologies-Reactive vs Proactive Measurements• Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy• The Clinical and Immunological Significance of Low Levels of Infliximab in the Absence of Anti-lnfliximab Antibodies in Patients With IBD• Antibodies to Adalimumab Predict Inflammation in Crohn's Patients on Maintenance Adalimumab Therapy• ATG16L1 Genotype Is Associated With Response to Anti-TNFWith Expert Commentary by:William J. Sandborn, MDProfessor and Chief, Division of Gastroenterology Director, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.
Gastroenterol Hepatol (N Y). 2014 Jul;10(7 Suppl 4):1-20.
4
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.
Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24.
5
A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.
Gastroenterol Hepatol (N Y). 2013 Aug;9(8 Suppl 4):1-16.
6
7
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
8
A review of infliximab use in ulcerative colitis.
Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014.
9
Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Expert Opin Biol Ther. 2017 Nov;17(11):1325-1332. doi: 10.1080/14712598.2017.1363885. Epub 2017 Aug 18.
10
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. doi: 10.1016/j.cgh.2018.05.026. Epub 2018 May 29.

引用本文的文献

1
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.
Saudi J Gastroenterol. 2023 Dec 15;30(4):181-97. doi: 10.4103/sjg.sjg_318_23.
2
Potential neurological manifestations of COVID-19: a narrative review.
Postgrad Med. 2022 May;134(4):395-405. doi: 10.1080/00325481.2020.1837503. Epub 2021 Jan 11.
3
A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.
Drugs. 2019 Jul;79(10):1053-1063. doi: 10.1007/s40265-019-01141-w.
4
Management of Inflammatory Bowel Disease During Pregnancy.
Dig Dis Sci. 2016 Aug;61(8):2194-2204. doi: 10.1007/s10620-016-4139-9. Epub 2016 Apr 11.
5
Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management.
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):156-71. doi: 10.4292/wjgpt.v6.i4.156.

本文引用的文献

1
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.
Clin Pharmacol Ther. 2012 Apr;91(4):635-46. doi: 10.1038/clpt.2011.328. Epub 2012 Feb 22.
2
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.
Inflamm Bowel Dis. 2012 Aug;18(8):1470-9. doi: 10.1002/ibd.21896. Epub 2011 Dec 6.
3
Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
MAbs. 2011 Nov-Dec;3(6):535-45. doi: 10.4161/mabs.3.6.17815. Epub 2011 Nov 1.
4
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Gastroenterology. 2011 Oct;141(4):1194-201. doi: 10.1053/j.gastro.2011.06.054. Epub 2011 Jun 30.
5
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.
Gut. 2012 Feb;61(2):241-7. doi: 10.1136/gutjnl-2011-300049. Epub 2011 Jun 5.
6
Development of the Crohn's disease digestive damage score, the Lémann score.
Inflamm Bowel Dis. 2011 Jun;17(6):1415-22. doi: 10.1002/ibd.21506. Epub 2010 Nov 28.
7
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
Scand J Gastroenterol. 2011 Mar;46(3):310-8. doi: 10.3109/00365521.2010.536254. Epub 2010 Nov 18.
8
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
MAbs. 2010 Jul-Aug;2(4):428-39. doi: 10.4161/mabs.12304. Epub 2010 Jul 1.
9
Infliximab, azathioprine, or combination therapy for Crohn's disease.
N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.
10
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. doi: 10.1124/jpet.109.153973. Epub 2009 Jun 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验